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3INSERM U 522, Universite´ de Rennes 1 and IFR 140, CHU Pontchaillou, 35033 Rennes, FranceThe cross-talk which has taken place in recent years between clinicians and scientists has resulted in a greater under-
standing of iron metabolism with the discovery of new iron-related genes including the hepcidin gene which plays a critical
role in regulating systemic iron homeostasis. Consequently, the distinction between (a) genetic iron-overload disorders
including haemochromatosis related to mutations in the HFE, hemojuvelin, transferrin receptor 2 and hepcidin genes
and (b) non-haemochromatotic conditions related to mutations in the ferroportin, ceruloplasmin, transferrin and di-metal
transporter 1 genes, and (c) acquired iron-overload syndromes has become easier. However, major challenges still remain
which include our understanding of the regulation of hepcidin production, the identiﬁcation of environmental and genetic
modiﬁers of iron burden and organ damage in iron-overload syndromes, especially HFE haemochromatosis, indications
regarding the new oral chelator, deferasirox, and the development of new therapeutic tools interacting with the regulation
of iron metabolism.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V.
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Since the discovery of the HFE gene in 1996 [1],
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morphogenic protein; BMPR, bone morphogenic protein receptor;
C/EBP, CCAAT/enhancer binding protein; DIOS, dysmetabolic iron-
overload syndrome; DMT, divalent metal transporter; ERK, extra-
cellular regulated MAP kinase; GDF, growth diﬀerentiation factor;
Hamp, hepcidin anti-microbial peptide; HAS, Haute Autorite´ de Sa-
nte´; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIF,
hypoxia-inducible factor; HJV, hemojuvelin; IL, interleukin; INSER-
M, Institut National de la Sante´et de la RechercheMe´dicale; JAK,
Janus kinase; LIC, liver iron concentration; MAP, mitogen activated
protein; MRI, magnetic resonance imaging; NTBI, nontransferrin
bound iron; ROS, reactive oxygen species; STAT, signal transducer
and activator of transcription; TfR, transferrin receptor; TGF, trans-
forming growth factor.mendously fruitful, resulting in a better understanding
of iron metabolism with the discovery of new iron-
related genes including the hepcidin gene which plays a
critical role in regulating systemic iron homeostasis.
Consequently, the classiﬁcation and management of
human disorders in this area have been greatly clariﬁed.2. Iron metabolism: the central role of the liver through
hepcidin production
Once iron has entered the body, it is reutilized in a
closed circuit, since daily iron loss is limited and not reg-
ulated according to iron stores. The only regulatory tar-
get of iron balance is intestinal iron absorption.
Hepcidin – a 25-amino-acid peptide initially identiﬁed
in human plasma and urine as an anti-microbial mole-
cule [2,3] and later found to be over-expressed in iron-
overloaded mice [4] and in experimental inﬂammation
[4,5] was recently demonstrated to be the major regula-
tor of intestinal iron absorption, and, more precisely, of
iron delivery to the plasma through the modulation ofed by Elsevier B.V. Open access under CC BY-NC-ND license.
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phages and placenta cells [6–8] (Fig. 1).
Hepcidin interacts directly with the iron export
molecule, ferroportin, causing its internalization and
subsequent degradation, blocking iron release from
cells to plasma [9]. Hepcidin is mainly produced by
hepatocytes making the liver the conductor of the
regulation of systemic iron homeostasis, although
there is some evidence that adipocytes [10] and mac-
rophages [11] can also synthetize hepcidin, but at a
lower level.
Hepcidin production is up-regulated by body iron
excess and inﬂammation [4,5,12] and downregulated
by anemia and hypoxia [12]. Such a regulation occursHepatocyte
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Fig. 1. Hepcidin is synthesized by hepatocytes. Hepcidin binding to ferroport
macrophage membranes, results in internalization and degradation of ferropo
decrease systemic iron bioavailability and, then, to decreased parenchymal ironmainly at the transcriptional level through several regu-
latory pathways (Fig. 2) [13]:
– The bone morphogenic protein (BMP) pathway has
emerged as an important piece of the puzzle [14].
As members of the TGFb superfamily, plasmatic
BMPs are involved in a number of important biolog-
ical processes including cell proliferation, diﬀerentia-
tion and apoptosis. Their binding to the BMP 1 and 2
receptors activates the phosphorylation of SMADs 1,
5 and 8 (R-SMAD), which then interact with SMAD
4. The complex migrates into the nucleus and, by
binding to speciﬁc DNA motifs in the hepcidin pro-
moter, regulates hepcidin gene transcription [15].egahporcaM
Iron
in, an iron transporter located at the basolateral part of enterocyte and
rtin, and then in decreasing cellular iron egress which, in turn, leads to
stores and to increased macrophagic iron stores. Tf, transferrin.
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Fig. 2. Schematic presentation of pathways regulating transcription of the hepcidin gene [1]. The bone morphogenic protein (BMP) pathway involves a
complex consisting of BMP receptors I and II (BMPR-I and BMPR-II), GPI-anchored hemojuvelin (HJV) and BMPs which activate SMAD 1, 5 and 8
phosphorylation. Phosphorylated SMADs 1, 5 and 8 bind to SMAD 4 and then migrate into the nucleus where they activate hepcidin transcription [2]. The
STAT 3 pathway is activated through JAK1/2 by the binding of IL-6 to its receptor at cell surface. Whether STAT 3 acts on hepcidin transcription only
directly or also through the SMAD complex remains to be elucidated [3]. The complex associating transferrin (Tf), transferrin receptor 1 (TfR-1) and
HFE as well as the binding of holotransferrin to transferrin receptor 2 (TfR-2) could also lead to hepcidin transcription by several putative mechanisms.
Solid lines: known pathways – dotted lines: hypothetic pathways. From Anderson et al. [13].
Y. Deugnier et al. / Journal of Hepatology 48 (2008) S113–S123 S115BMPs 2, 4 and 9 have a strong stimulatory eﬀect on
hepcidin synthesis [16]. The hemojuvelin (HJV),
HFE and transferrin receptor 2 (TfR2) proteins –
whose mutation results in human haemochromatosis
– may modulate hepcidin expression likely by inter-
acting along the BMP pathway. HJV, a member of
the repulsive guidance molecule family proteins, is a
glycosylphosphatidylinositol (GPI)-linked membrane
protein mainly expressed in the liver and skeletal
muscle [17]. The BMP pathway is activated by the
interaction of GPI-anchored HJV with the type 1
BMP receptor. This activation is counteracted by
the soluble form of HJV. Mechanisms involved in
the modulation of hepcidin expression related to
TfR2 and HFE are not fully understood. It is likely
that HFE acts through its binding to TFR1 and
TfR2 [18]. The role of ERK1/ERK2 and p38 MAP
kinases in the signal transduction related to TfR2
has also been suggested [19].
– Another pathway whose activation leads to increased
hepcidin production independently of HJV corre-
sponds to the STAT3 pathway which is activated by
interleukin 6 (IL-6) through JAK1/2 [20,21] and results
in hepcidin transcription either directly or through the
interaction between STAT 3 and SMAD [15].– The hepatic-enriched transcriptional factor C/EBPa
involved in the hepatic diﬀerentiation process has
also been demonstrated to be active in the control
of hepcidin transcription [22].
Although huge advances have been made in our
understanding of iron metabolism and its regulation,
much remains to be learned. How the liver is informed
about body iron requirements is still unknown. Diferric
transferrin has emerged as the potential signaling mol-
ecule related to iron stores [23] whilst hypoxia-induc-
ible factor (HIF), transcriptional factor and the
plasmatic growth diﬀerentiation factor 15 (GDF15), a
member of the TGFb superfamily, have been proposed
as signaling hypoxia and erythroid activity, respectively
[24].3. Classiﬁcation of hepatic iron storage disorders: a new
vision
Thanks to molecular genetics tools, a distinction
between genetic and acquired hepatic iron-overload
can be currently more easily made, even if environmen-
tal factors may be involved in hereditary iron storage
S116 Y. Deugnier et al. / Journal of Hepatology 48 (2008) S113–S123disorders and genetic factors are likely to modulate iron
burden in acquired iron-overload diseases.
Genetic iron-overload disorders may be divided into
haemochromatotic and non-haemochromatotic forms
according to patho-physiological and phenotypic crite-
ria (Table 1).
Haemochromatosis should currently refer to hereditary
iron-overload disorders presenting with a deﬁnite and
common phenotype characterized by normal erythropoi-
esis, increased transferrin saturation and parenchymal
distribution of iron deposition, and related to an inaccu-
rate production and/or regulation and/or activity of hep-
cidin [25] (Figs. 3 and 4). Based upon such a deﬁnition,
haemochromatosis consists of ﬁve diﬀerent genetic
disorders.
– By far, the most common is HFE haemochromatosis
(type 1 haemochromatosis) that represents more than
90% of iron-overload syndromes of genetic origin. It
corresponds to the classical HLA-linked haemochro-
matosis and is transmitted as an autosomal recessive
trait.
– The other forms are much less frequent. Some
may cause early and severe iron burden. The dis-
covery of their causal mutations has played a cru-
cial role in furthering our understanding of iron
metabolism:
 Juvenile haemochromatosis (type 2 haemochro-
matosis) is related to mutations on either the
hemojuvelin (HJV) gene (type 2A) [17] or the hep-
cidin (HAMP) gene (type 2B) [17] and usually
results in a severe autosomal recessive disorder
of early onset,
 Transferrin receptor 2 (TFR2) haemochromatosis
(type 3 haemochromatosis) is related to muta-
tions in the TFR2 gene [26] and is responsible
for an autosomal recessive disorder very similar
to HFE haemochromatosis,
 Finally, type B ferroportin disease (see below)
may rarely result in a typical haemochromatotic
phenotype [27].Table 1
Main characteristics of genetic iron overload disorders
Genetic iron-overload disease Gene Chromosome
Haemochromatotic
HFE HFE 6p21.3
Hemojuvelin HJV 1p21
Hepcidin HAMP 19q13.1
Transferrin receptor 2 TfR2 7q22
Ferroportin disease type B SLC40A1 2q32
Nonhaemochromatotic
Ferroportin disease type A SLC40A1 2q32
A(hypo)ceruloplasminemia Ceruloplasmin 3q23-q25
A(hypo)transferrinemia Transferrin 3q21Nonhaemochromatotic iron-overload disorders
include:
– The autosomal dominant type A ferroportin disease –
ill-named as type 4 haemochromatosis – caused by
mutations in the ferroportin (SLC40A1) gene and pre-
senting with mesenchymal iron-overload and low or
slightly elevated transferrin saturation [27],
– Two exceptional disorders transmitted as autosomal
recessive traits
 hereditary a(hypo)ceruloplasminemia [28,29]
related to mutations in the ceruloplasmin gene
and responsible for haematological (microcytic
anemia), neurological (retinal degeneration,
extrapyramidal syndrome, cerebellar ataxia,
and dementia) and metabolic (diabetes) symp-
toms and both low-serum iron and transferrin
saturation,
 hereditary a(hypo)transferrinemia [30] related to
mutations in the transferrin gene and expressed
as severe iron deﬁciency anemia and parenchy-
mal iron-overload, and
– Some cases of mutations in the DMT1 (divalent metal
transporter) gene [31–33] also resulting in both micr-
ocytic anemia and hepatic iron excess.
Acquired iron-overload disorders correspond to a
more heterogeneous group of diseases:
– Chronic excessive iron supply may result in a clini-
cally signiﬁcant increase of hepatic iron stores as
recently reported in elite road cyclists [34].
– Haematological disorders including thalassemia,
myelodysplastic syndromes, congenital dyserythro-
poietic anemias, red cell enzyme deﬁciencies, sickle
cell disease and other haemoglobinopathies are
responsible for hepatic iron excess through both (i)
the downregulation of hepcidin production by an ery-
throid factor – such as GDF15 – produced in excess
[24] and (ii) multiple blood transfusions [35],Transmission Onset Clinical expression
Recessive Late Articular and hepatic
Recessive Early Cardiac and endocrine
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Fig. 3. Schematical patho-physiology of parenchymal iron-overload in haemochromatosis. Defective production, regulation or eﬀect of hepcidin related to
mutations in the HFE, hemojuvelin, transferrin receptor 2 or hepcidin gene (as roughly indicated by a cross) opens iron egress from intestinal and
macrophagic cells. This results in increased iron inﬂux into plasma and, then, in increased transferrin (Tf) saturation and in the production of a special
form of iron, non-transferrin-bound iron (NTBI), which is avidly taken up by parenchymas.
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hepatic iron stores through both the liver damage
itself and its cause.
 The phagocytic process secondary to chronic
necro-inﬂammatory hepatocytic damage may
result in iron redistribution toward Kupﬀer cells,
but hepatic iron excess remains usually slight. In
end-stage liver cirrhosis, additional and some-
times massive parenchymal iron-overload may
occur [36,37] in relation to decreased transferrin
and hepcidin synthesis secondary to hepatic
insuﬃciency [38]. This leads to a pseudo-haemo-
chromatotic cirrhosis pattern with increased
transferrin saturation and ferritin levels whose
diagnosis can be made on (i) the absence of hae-mochromatosis mutation, (ii) the heterogeneous
distribution of iron throughout the liver at
MRI [39], and (iii) the absence of iron deposits
within ﬁbrous septa at liver biopsy [39].
 More speciﬁc mechanisms resulting in the
development of hepatic iron excess have been
suggested in chronic hepatitis C and in steato-
hepatitis. It has been proposed that interaction
between the hepatitis C virus (HCV) and HFE
might explain, at least partly, HCV-associated
liver siderosis [40]. Alcohol has been shown
to have an inhibitory eﬀect on hepcidin
synthesis which could participate in alcohol-
related liver siderosis [41]. With respect
to non-alcoholic steatohepatitis, data are
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Serum
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Fig. 4. Natural course, phenotype and penetrance of C282Y homozygosity. A 5-stage classiﬁcation was recently proposed by the French Haute Autorite´
de Sante´ (HAS) [84] as the basis for its clinical recommendations on the management of HFE haemochromatosis: stage 0 corresponds to unexpressed
genetic predisposition, stage 1 to increased transferrin saturation (>45%) only, stage 2 to increase in both transferrin saturation and serum ferritin
(>200 lg/L in women and >300 lg/L in men), stage 3 to symptoms resulting in impaired functional prognosis (chronic fatigue and arthralgias) and stage 4
to organ damage with life-threatening disorders, especially diabetes, cardiomyopathy, liver cirrhosis and hepatocellular carcinoma (HCC). The
approximate percentage of patients at each stage (%) clearly indicates incomplete penetrance of C282Y homozygosity.
S118 Y. Deugnier et al. / Journal of Hepatology 48 (2008) S113–S123contradictory. On one hand, an association
between unexplained, mixed and mild hepatic
iron-overload and various metabolic abnormal-
ities including moderate overweight with visceral
distribution of fat, high blood pressure, dysli-
pidemia and abnormal glucose metabolism,
has been described under the name of insulin
resistance-associated iron-overload or dysmeta-
bolic iron-overload syndrome (DIOS) [42,43].
On the other hand, hepcidin synthesis by the
visceral adipose tissue resulting in low iron
stores has been reported in morbid obesity
[10], and hyperhepcidinuria has been docu-
mented in patients with DIOS by Lore´al
et al. quoted in [44]. This could suggest a
hepcidin-resistance state in subjects with DIOS.4. Expressivity of iron-overload syndromes: the lesson
from haemochromatosis
The discovery of theHFE gene [1] has allowed for large
genotypic/phenotypic correlation studies [45–48]. These
studies demonstrated that, contrary to previous thought,
C282Y homozygosity, the common genotype associated
with more than 90% of HFE haemochromatosis cases in
European populations, had lower penetrance than
expected (Fig. 4). According to series, gender and diseasedeﬁnition, biochemical expressivity ranged between 50%
and 95% whilst clinical penetrance was calculated as 1%
when considering the full blown disorder [46], as 11%
when considering liver cirrhosis [48], and between 10%
and 50% when considering clinical symptoms including
fatigue and arthralgias [47]. Moreover, all subjects with
biochemical expression were found not to further develop
clinical symptoms [49]. Then, the question arose why the
penetrance of HFE haemochromatosis had such a large
range and was so unforeseeable. Recent studies focusing
on environmental and genetic modiﬁers of HFE haemo-
chromatosis launched the concept that modifying factors
could be diﬀerent according to the criteria used for deﬁn-
ing haemochromatosis penetrance, and suggested to dis-
tinguish penetrance of iron burden as assessed on serum
ferritin levels, liver iron concentration and/or the amount
of removed iron and clinical penetrance based upon the
type and severity of clinical symptoms (liver damage,
arthropathy, abnormalities in glucose metabolism. . .)
[50].4.1. Modiﬁers of iron burden
4.1.1. Environmental modiﬁers
Exposure to every factor susceptible to modify iron
metabolism should theoretically inﬂuence the amount
of body iron excess. In fact, there is little evidence for
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burden probably because (i) iron accumulation is a long
process, (ii) factors exerting opposite eﬀects on iron
stores often coexist or follow one another over time,
and (iii) in vivo methods assess the absorption of non-
haem iron and not that of haem iron which is signiﬁ-
cantly involved in the development of iron excess in
haemochromatosis.
4.1.1.1. Diet. A signiﬁcant but weak correlation was
found between serum ferritin levels and haem dietary
intake in haemochromatotic subjects [51], especially in
menopausal women [52]. In addition, the amount of
iron to be removed annually in order to maintain low
body iron stores has been shown to be slightly lower
in haemochromatotic patients who regularly drink tea
– which decreases iron absorption – than in those who
do not [53]. These data suggest that diet has a relatively
modest inﬂuence on iron stores in the haemochromatot-
ic patient.
4.1.1.2. Alcohol. Alcohol is responsible for a decrease
of hepcidin transcription (i) directly by decreasing the
expression and/or activity of the transcriptional fac-
tor C/EBPa [54], likely through its eﬀect on ROS
production [55,56], and (ii) indirectly due to hepatic
insuﬃciency secondary to the chronic liver disease it
leads to [38]. Then, on the long-term, chronic alcohol
consumption should result in aggravating iron
burden.
4.1.1.3. Blood donation. Barton et al. [57] reported that
body iron stores as measured by phlebotomies were
not diﬀerent in C282Y homozygotes whether they had
been previously blood donors or not. This suggests that
post-donation enhancement of intestinal iron absorp-
tion could compensate infrequent blood loss.
4.1.1.4. Metabolic syndrome. In a genotypic/phenotypic
correlation study performed in a large French general
population, under-expression of C282Y homozygosity
– as judged by transferrin saturation – was found to
be associated with obesity [58]. This, together with the
demonstration that visceral adipose tissue of obese
patients was able to produce hepcidin [10], supports
that, in haemochromatotic patients with increased fat
mass, iron burden could be decreased thanks to extra-
hepatic production of hepcidin [44].
4.1.1.5. Inﬂammation. Acute inﬂammation was shown
to decrease transferrin saturation in C282Y homozyg-
otes. Whether chronic inﬂammatory state may result
in decreasing iron burden was addressed by Beutler
et al. [59]. These authors measured the levels of C-reac-
tive protein and of IL-6 in C282Y homozygotes and
failed to ﬁnd any relationship between iron burden asassessed by phlebotomy and the levels of inﬂammatory
markers.
4.1.1.6. Drugs. A recent study showed that the admin-
istration of a proton-pump inhibitor resulted in
decreasing phlebotomy requirements in C282Y homo-
zygous patients, probably by suppressing gastric acid-
ity which is necessary for iron absorption [60].
Otherwise, nifedipine, a L-type calcium channel
blocker, has been proposed as a putative pharmaco-
logical agent for the treatment of iron-overload
because of its eﬀect on DMT1 resulting in modulating
iron mobilisation from the liver and increasing urinary
iron excretion [61].
4.1.1.7. Helicobacter pylori infection. Although Helico-
bacter pylori infection is associated with iron deﬁ-
ciency and impairs response to iron therapy, the
level of iron burden was not diﬀerent in C282Y homo-
zygotes with and without antibodies against helicobat-
er pylori [62].
4.1.2. Genetic modiﬁers
4.1.2.1. Gender-associated factors. It is widely accepted
that, in haemochromatosis, iron burden is usually lower
in women than in men. This was demonstrated by Moi-
rand et al. [63] who compared age-matched male and
female haemochromatotics, and further conﬁrmed by
phenotypic/genotypic studies [45–48]. Whether this pro-
tective eﬀect of gender is only related to physiological
events remains debated. Indeed, if early menopause
and hysterectomy are associated with either earlier or
increased iron burden in haemochromatotic women,
no signiﬁcant correlation has been found between the
number of pregnancies and body iron stores [63].
4.1.2.2. Iron metabolism-related genes. By showing corre-
lated serum ferritin levels in fraternal and identical sib-
lings, early family studies have suggested that such
modiﬁers could be involved in the penetrance of HFE
haemochromatosis. Recent studies have focused on
genes involved in the regulation of hepcidin production
and reported that (i) co-inheritance of mutations in the
hepcidin gene [64,65] or in the HJV gene [66] together
with C282Y homozygosity was associated with more
severe iron burden of earlier onset and (ii) common vari-
ants in the BMP pathway were associated with iron bur-
den [67], which suggests that full expression of HFE
haemochromatosis is linked to abnormal hepatic expres-
sion of hepcidin, through both impairment in HFE
function and functional modulation in the BMP path-
way. It is likely that forthcoming genotypic studies using
high output genotyping will address not only the regula-
tory pathways of hepcidin synthesis but also all genes
involved in cellular iron metabolism, including iron
transporter genes.
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Alcohol acts not only on the level of iron burden but
also on the severity of liver disease in HFE haemochro-
matosis, since, for the same level of hepatic iron stores,
haemochromatotic patients with excessive alcohol
intake are more prone to develop early and severe liver
ﬁbrosis than those who are either abstinent or moderate
drinkers [68,69]. Similarly, overweight and steatosis have
been reported to be associated with an increased risk of
ﬁbrosis in C282Y homozygotes [70] despite obesity that
could result in lowering iron burden in these patients
[44].
It is likely that, besides these acquired factors, genetic
modiﬁers may modulate the degree of organ damage.
Recently, Valenti et al. reported that the superoxide dis-
mutase genotype aﬀected the risk of cardiomyopathy
[71] and Osterreicher et al. found that TGFb1 codon
25 gene polymorphism was associated with cirrhosis in
patients with haemochromatosis [72]. Candidate genes
are not only those involved in regulating oxidative stress
and ﬁbrogenesis, but also all those involved in prolifer-
ation and apoptosis balances, tissue repair and speciﬁc
organ metabolisms [50].5. Management of hepatic iron-overload disorders: easier
and promising
Advances in imaging – allowing for a non-invasive
diagnosis of hepatic iron-overload – and in molecular
genetics – allowing for identiﬁcation of most mutations
involved in hereditary iron-overload disorders – have
dramatically simpliﬁed the diagnostic procedures in
front of the suspicion of iron excess, while the availabil-
ity of new oral chelators, the discovery of hepcidin and
our better understanding of iron metabolism are open-
ing up perspectives on future therapies.
5.1. Diagnosis
The ﬁrst step consists of (i) evaluating the clinical
expression of the putative iron-overload syndrome on
the basis of age and of the type (hepatic/extra-hepatic)
and severity of symptoms and (ii) assessing serum ferri-
tin, knowing that frequent conditions are susceptible to
increase serum ferritin levels in the absence of elevated
body iron stores, through either cell necrosis (hepati-
tis. . .) or increased ferritin synthesis (acute and chronic
inﬂammation, chronic alcohol consumption, insulin
resistance. . .).
The second step consists of assessing transferrin satu-
ration knowing that (i) normal transferrin saturation
allows to rule out haemochromatosis except in case of
coexistent inﬂammatory syndrome [73] or obesity [58],
and (ii) increased transferrin saturation is not speciﬁcof haemochromatosis, but can be related to laboratory
error – which implies having a conﬁrmation of the test
at least once –, to excessive iron release from damaged
cells (i.e. hepatitis, haemolysis. . .) or to decreased syn-
thesis of transferrin secondary to hepatocellular insuﬃ-
ciency. Then,
– If transferrin saturation is increased and conﬁrmed as
elevated at least once, HFE testing is indicated:
 The ﬁnding of C282Y homozygosity allows to
establish the diagnosis of HFE haemochromato-
sis. Then, disease stage has to be assessed and,
according to stage, either follow-up or venesec-
tion therapy has to be proposed (Fig. 4).
 The ﬁnding of any other HFE genotype must be
interpreted with caution since (i) compound
C282Y/H63D heterozygosity does not result in
clinically relevant iron-overload, even if 20–25%
of compound heterozygotes present with mild
increase in transferrin saturation and 10% with
slight hepatic iron excess [74], and (ii) H63D
homozygosity, C282Y heterozygosity and
H63D heterozygosity may never explain abnor-
mal serum iron and ferritin levels in the absence
of an associated cause of impaired iron metabo-
lism. Then, in case of increased transferrin satu-
ration in a non-C282Y homozygous subject,
non-HFE haemochromatosis becomes an option
once (i) liver disease and haematological disor-
ders have been ruled out and (ii) iron excess
has been proven by direct assessment, i.e. by
MRI or liver biopsy. HJV or HAMP juvenile
haemochromatosis will be considered ﬁrst in
young patients with severe iron excess resulting
in heart and endocrine symptoms whilst type B
ferroportin disease, TfR2 haemochromatosis,
and rare mutations in the HFE gene will be ﬁrst
sought for in case of mild and late symptoms,
mainly related to joints and liver. However, late
onset of juvenile haemochromatosis has been
reported as well as early and severe disease in
transferrin receptor 2 haemochromatosis. In any
case, documenting serum iron and ferritin levels
in ﬁrst-degree relatives may be helpful.
– If transferrin saturation is either slightly increased,
normal or low, it is mandatory to answer the question
whether hyperferritinemia corresponds to iron excess
or not. This can be done by either (i) MRI which
enables the assessment of liver iron concentration
provided the apparatus has been well calibrated and
a validated algorithm is used (http://www.radio.
univ-rennes1.fr) [39], and allows for evaluation of
iron distribution in the liver, spleen, pancreas and
bone marrow [75], (ii) liver biopsy which also pro-
vides diagnostic information regarding associated
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ﬁbrosis. . .) [76], or (iii) retrospectively by phlebot-
omy. In this setting, the most common diagnosis is
that of DIOS. In the absence of metabolic abnormal-
ities and/or confronted with a signiﬁcant iron-over-
load (LIC > 150 lmol/g and/or removed iron
>2,5 g), rare genetic causes of iron excess may be
sought for, especially (i) type A ferroportin disease
responsible for mesenchymal iron excess which
results in a suggestive low MRI signal in both the
liver and spleen [75] and is usually associated with
no or mild symptoms, even in the presence of severe
iron-overload [77], and (ii) hereditary a(hypo)cerulo-
plasminemia, the only systemic iron-overload syn-
drome resulting in neurological symptoms
(extrapyramidal syndrome, retinal degeneration, cer-
ebellar ataxia, dementia. . .), which is easily diagnosed
by the ﬁnding of either undetectable or low-serum
ceruloplasmin levels [28,29].
Indication for liver biopsy in the management of
patients with hepatic iron-overload is currently limited.
In C282Y homozygotes, liver biopsy is no longer neces-
sary except for grading hepatic ﬁbrosis and, if necessary,
searching for associated lesions. Guyader et al. [78] dem-
onstrated that, in C282Y homozygotes, when the liver
was not clinically enlarged AND serum ferritin level
was lower than 1000 ng/ml AND serum AST level was
normal, there was never signiﬁcant liver ﬁbrosis found.
On the contrary, when one, two or all these conditions
were not met, there was a signiﬁcant risk of ﬁbrosis.
The question whether ﬁbrosis was susceptible to regress
or not with venesection therapy was recently addressed
by Falize et al. [79] in 36 C282Y homozygotes presenting
with severe ﬁbrosis on their initial liver biopsy. These
authors demonstrated that ﬁbrosis regressed in 69% of
patients with initial bridging ﬁbrosis and in 35% of
patients with initial cirrhosis. In addition, they proposed
a predictive index for ﬁbrosis regression based upon
gammaglobulins, platelet count and prothrombin activ-
ity. When non-invasive predictive tests of liver ﬁbrosis–
including biochemical markers and elastometry – are
applied and validated in C282Y homozygotes, it is likely
that indications for liver biopsy for ﬁbrosis assessment
will become anecdotical. In non C282Y homozygotes,
indication for liver biopsy may remain for both diagnos-
tic and prognostic purposes, especially in patients with
signiﬁcant (i.e. LIC > 150 lmol/g – N < 36) iron-over-
load of unknown origin or in those with DIOS present-
ing with increased serum hyaluronate [80].
5.2. Treatment
Venesection therapy remains the standard treatment
for HFE, non-HFE haemochromatosis and acquired
iron-overload conditions unrelated to haematologicaldisorders. Reducing iron intake does not seem to be
useful. Nutritional advice can only advocate a balanced
diet with low alcohol intake, no excessive vitamin C
supplementation and, possibly, consumption of tea.
Despite the risk of anemia, venesection therapy
remains the usual treatment in type A ferroportin dis-
ease. In other forms of iron-overload, phlebotomies are
contra-indicated. Subcutaneous infusions of desferriox-
amine have been reported to be eﬃcient in individual
cases of aceruloplasminemia [81,82] and, together with
deferiprone (CP 20 or FerriproxTM), have been the only
means to reduce iron burden in iron-loading anemias.
Recently, a new oral chelator, deferasirox (ICL670 or
ExjadeTM), a tridented triazole component, was
launched. In thalassemic patients, at a dosage of 20–
30 mg/kg/day, it was found as eﬃcient as desferriox-
amine and well tolerated despite the report of gastro-
intestinal symptoms in 25% of patients and a mild
increase of serum creatinine in 33% [83]. In most cases,
these side-eﬀects were benign and compatible with the
continuation of therapy. Deferasirox has become the
treatment of choice of iron-loading anemias. If its
long-term tolerance is conﬁrmed to be satisfactory, it
could be an adjunct therapy to and, even, replace vene-
section therapy in haemochromatosis.
It is likely that, in the near future, pharmacological
agents interacting with hepcidin production will make
possible to treat hepcidin deﬁciency in haemochroma-
tosis and hepcidin excess in inﬂammatory anemia.
Pharmacological manipulation of iron transport mole-
cules using speciﬁc (ant)agonists will make it possible
to target iron metabolism abnormalities with precision.
Besides these therapeutic challenges, there remains a
genetic challenge consisting of the identiﬁcation of
genes modulating iron burden and the consequent
organ damage, and their application to predictive
medicine.
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